Fiche détaillée de la technologie

 
Titre de la technologie / Technology Title
    Immunisation avec superoxide dismutase mutante pour le traitement de maladies neurodégénératives
Description / Description
    At present there is no effective treatment for Amyotrophic Lateral Sclerosis (ALS). A novel approach for treatment based on either active immunisation, vaccination with recombinant superoxide dismutase (SOD1), or passive immunisation with antibodies against SOD1 species has been tested with success in mice. This therapeutic approach is based on reduction of toxic SOD1 mutant and it would not interfere with other drug treatment. Moreover, monoclonal antibodies using the hybridoma technology have been derived against SOD1 species. Of particular interest is the availability of unique monoclonal antibodies that recognizes specifically the mutant forms of SOD1 linked to ALS and not the normal (WT) SOD1. Such monoclonal antibodies can also be applied for diagnosis of ALS caused by SOD1 mutations.
Fiche descriptive / Fact sheet
    Inventeur / Inventor Collaborateur(s) / Collaborator(s)
    • Makoto Urushitani
    Contact / Contact Champs(s) d'intérêt(s) / Industry segment(s) Brevet(s) / Patent(s) Numéro de la technologie / File Number : 00651
    www.ulaval.ca